After launching an investigation into the business practices of Express Scripts Canada in November 2024, the Competition Bureau of Canada has announced that it has closed the case. The investigation did not uncover sufficient evidence to establish that this major player in the pharmaceutical sector had violated federal competition laws.
The Bureau had announced the investigation in April 2025. "The investigation focused on allegations that the company used preferred provider networks to steer patients toward affiliated pharmacies and employed service fees and audit practices to disadvantage competing pharmacies."
In a position statement released on November 16, 2026, the Bureau says it closed its investigation in September after concluding that there was insufficient evidence to warrant intervention.
In its news release, however, the Bureau states that it "remains concerned that preferred provider network arrangements may, in certain circumstances, harm competition, patient choice and the ability of pharmacies to compete."
Preferred provider networks
Express Scripts Canada is owned by The Cigna Group, a global health services company based in the United States. The company is known for providing electronic claims adjudication services for prescription drugs to plan sponsors, third-party administrators and pharmacies.
Electronic claims processing allows patients to pay only the portion of their prescription costs that is not covered by their insurance. Pharmacies generally must enter into an agreement with the pharmacy benefits manager used by the patient's insurer.
Preferred provider networks allow patients to benefit from more favourable terms. However, in the case of a mandatory or closed network, they restrict patients' choice of pharmacy.
The Bureau's investigation sought to determine whether Express Scripts Canada was violating section 79 of the Competition Act by engaging in a practice or conduct that substantially harms competition. The Bureau wanted to determine whether Express Scripts Canada was abusing its dominant position by:
- engaging in self-preferencing by using preferred provider networks that force or induce patients to use an Express Scripts owned or associated pharmacy, rather than a pharmacy of choice;
- squeezing the margins of rival pharmacies through pharmacy benefits manager service fees and audit practices.
The finding of insufficient evidence applies to both aspects of the investigation. If new information indicates that a preferred provider network raises the competition concerns outlined above, the Bureau says it will not hesitate to take appropriate action.
Five factors to watch
In its statement, the Bureau identifies five factors intended to help industry participants determine the circumstances in which competition concerns may arise:
- One or more parties to the preferred provider network have market power.
- One or more parties to the preferred provider network are vertically integrated.
- The preferred provider network limits which pharmacies can participate.
- The preferred provider network requires or strongly incentivizes use of in-network pharmacies.
- The share of patients captures by the preferred provider networks is large.